WELL-ESTABLISHED SAFETY PROFILE BASED ON THE LARGEST PATIENT POPULATION STUDIED FOR A COPD BIOLOGIC

Safety data from 3 phase 3 trials including a 2-year study Safety data from 3 phase 3 trials including a 2-year study Over two thousand patients: NUCALA n=1043, placebo n=1046) Over two thousand patients: NUCALA n=1043, placebo n=1046)

ADVERSE REACTIONS ≥3% WITH NUCALA AND MORE COMMON THAN PLACEBO

(MATINEE: 52-104 WEEKS, METREX & TRIAL 3*: 52 WEEKS)

Adverse reactions greater than or equal to 3% with NUCALA and more common than placebo Adverse reactions greater than or equal to 3% with NUCALA and more common than placebo

Herpes zoster: Across the 3 COPD trials, 1% NUCALA and 0.7% placebo.

*Trial 3 was a 52-week dose-ranging COPD trial with NUCALA vs placebo in 449 adults with BEC ≥150 cells/μL at screening or ≥300 cells/μL in prior year.1

BEC=blood eosinophil count.

Navigate a NUCALA prescription

Start with MyNUCALA